Johnson & Johnson joins forces with Monash University-led partnership to advance novel technology aimed at saving lives of women in child birth

Description

The biggest cause of pregnancy-related death in resource-limited settings is excessive blood loss after birth, a condition effectively managed in developed countries with injectable oxytocin administered by trained personnel.

A novel form of oxytocin, an inhalable dry powder which that does not require refrigeration, has the potential to expand its reach and ease of use by frontline health workers and potentially mothers themselves.